Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA panel to take on knotty anti-NGF challenge

This article was originally published in Scrip

Executive Summary

The US FDA has been grappling with the knotty challenge of how to regulate an experimental class of drugs, known as anti-nerve growth factors (anti-NGFs), which regulators said "represent a potentially significant and novel strategy for the treatment of pain," but have been linked to osteonecrosis and avascular necrosis (AVN) – all leading to joint replacement – and wants a panel of outside experts to help the agency decide whether to permit drug makers to proceed with clinical testing.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts